Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q1 2016 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2015 Net Income-$903.46K-$903.46KN/M vs Q1 2015 EPS Diluted-$0.01-$0.01N/M vs Q1 2015 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flow-$424,869N/M ended Mar 31, 2016 · filed May 20, 2016 · 50 d after period end